Industry Reports Services Press Release
  •   Blogs
  • Contact us About us

    APAC Monoclonal Antibodies Market size is expected to cross USD 86 billion by 2028, according to a latest forecast report by Graphical Research.

    Surge in prevalence of chronic, infectious and rare diseases has led the market to experience momentous demand in diagnostic and therapeutic products. For instance, according to the WHO, cancer was one of the leading cause of deaths globally with over 10 million people dying due to cancer in 2020. Cancer accounts for one in every six deaths in the world each year. High prevalence has created huge opportunities for drug development and manufacturing. Number of approved monoclonal antibodies indicated for cancer treatment has exhibited revenue growth for industry players. Thus, increasing product adoption to reduce disease-associated mortality rate will boost the industry growth. Further, government initiatives and programs will stimulate product development activities. The World Health Assembly passed the Resolution, cancer prevention and control in the context of an integrated approach (WHA70.12) in 2017. This was aimed to urge governments and WHO to accelerate action that will help in reducing premature mortality from cancer. Therefore, overall increase in cancer patients, requiring effective and affordable therapies.

    Along with cancer, highly specific targeted therapies for autoimmune diseases and cardiovascular diseases influences the market demand. The advances in product development technologies have resulted into expanding applications of monoclonal antibodies as immunotherapeutic. These mAb products have also shown positive results as potential treatment of rare diseases that has further driven R&D activities in the field. Extensive product pipeline with potential effective therapies catering to such diverse range of diseases will result in the market expansion. Thus, with high product approval rate, contributing to increasing accessibility. As the manufacturers and innovative biopharmaceutical companies are proactively involved in the product development, mAbs have witnessed increasing clinical applications for several conditions including blood disorders, migraine, asthma, Crohn’s disease, transplants and other infectious diseases.

    The humanized monoclonal antibodies segment accounted 32% market share in 2021 attributed to various advantages offered by humanized mAbs over other types. Using the advanced genetic engineering technologies, companies have developed humanized monoclonal antibodies that are being used to treat various immunological diseases, cancer and many others. Some of the major humanized mAbs are Herceptin, Perjeta, Ocrevus among others. Continuous research to enhance drug specificity and development of effective therapies will enhance product demand for humanized monoclonal antibodies.

    Browse detailed statistical insights from the report, “Asia Pacific Monoclonal Antibodies Market Forecast 2028 By Type (Fully Human, Humanized, Chimeric), By Application (Oncology, Autoimmune Diseases, Infectious Diseases), By End-use (Hospitals, Specialty Centers), Research Report, Regional Outlook (Japan, China, India, Australia, South Korea, Singapore, Indonesia, Thailand, Malaysia, Philippines) COVID-19 Impact Statistics, Price Trends, Historic Data, Growth Prospects, Competitive Industry Share” along with the table of contents (ToC) @


    The autoimmune diseases segment will grow at 13.6% CAGR during the forecast period. Monoclonal antibodies have shown promising outcomes in the treatment of autoimmune diseases in last few years. Monoclonal antibodies have been an effective treatment option for conditions such Rheumatoid arthritis, Psoriasis, and multiple sclerosis among others. Some of the major drugs used to treat such diseases are adalimumab, ocrelizumab, infliximab, and tocilizumab among others. Moreover, researchers are continuously involved in developing new effective drugs for autoimmune disease treatment. Thus, increased usage of mAbs for treatment of autoimmune diseases will boost the market growth.

    The specialty centers segment was valued over USD 14 billion revenue in 2021, due to increase in establishments of specialty centers along with growing prevalence of infectious diseases. Specialty centers offer advanced medical care for severe and rare conditions. There has been increase in investment for developing technologically advanced specialty centers in Asian countries like China and India, which has attracted patients for medical care in such centers. Moreover, the pandemic has demonstrated the importance of high-quality treatment at specialty centers. Thus, high investment in medical infrastructure to provide top quality care will boost the market growth.

    India monoclonal antibodies market will witness 18.6% CAGR during forecast period, credited to huge patient population and increasing prevalence of chronic diseases such as cancer along with spread of deadly virus like COVID-19. Lack of existing treatment and huge demand for targeted treatment options for COVID-19 have encouraged number of companies to engage in clinical trials and drug development. Increasing R&D activity in the region is also one of the major factor pushing the regional market growth. Moreover, emergency authorization for the use of mAb therapeutics in the COVID-19 patients has also fuel the market size.

    The monoclonal antibodies in APAC market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2017 to 2028, for the following segments:

    Asia Pacific Market, By Type

    • Fully human
    • Humanized
    • Chimeric
    • Others

    Asia Pacific Market, By Application

    • Oncology
    • Autoimmune diseases
    • Infectious diseases
    • Others

     Asia Pacific Market, By End-use

    • Hospitals
    • Specialty centers
    • Others

    The above information has been provided for the following countries:

    • Asia Pacific
      • Japan
      • China
      • India
      • Australia
      • South Korea
      • Singapore
      • Indonesia
      • Thailand
      • Malaysia
      • Philippines